News Archive
Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.
Researchers at Lund University in Sweden may have discovered one of the keys to understanding how the body develops acute pancreatitis. The results offer hope for the development of drugs that specifically target the disease.
AIDS Healthcare Foundation (AHF), the US' largest non-profit HIV/AIDS healthcare provider, which provides medical care and/or services to more than 100,000 individuals in 21 countries worldwide, is honored to announce the September 24th grand opening of AHF's first AIDS treatment center in Washington, DC, where the HIV rate is now reported to be 3%—higher than the rate in Lagos, Nigeria.
Elsevier Business Intelligence, the medtech industry's leading strategic partner and investment conference organizer, hosted the year's largest annual strategic partnership and investment meeting, 'IN3 Medical Device Summit', on October 20-21 at San Francisco's InterContinental Mark Hopkins Hotel. This event followed Elsevier Business Intelligence's 'Medical Device Investor Day', also held at the InterContinental Mark Hopkins, on October 19.
The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma: symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.
› Verified 3 days ago